ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

ResMed Inc (RMD) reports an 8% revenue increase and plans to boost share buybacks, while navigating global trade challenges ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...

Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...

Mizuho lowered the firm’s price target on ResMed (RMD) to $250 from $265 and keeps an Outperform rating on the shares. The company reported ...

Piper Sandler lowered the firm’s price target on ResMed (RMD) to $248 from $260 and keeps a Neutral rating on the shares. The firm notes the ...

Resmed shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus forecast.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

Chief executive Mick Farrell says he’s confident the medical device company’s exports from Australia and Singapore will not ...